Today we announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.
Today we announced the treatment of the first patient in phase 1/2a clinical trial for NK cell therapy CYNK-101, in development for the first-line treatment of advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers.
Today we announced we are set to join the broad-market Russell 3000® and the Russell 2000® Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.
Today we announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.).
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its common stock at an exercise price of $8.25 per share (together the “Securities”) in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions.
Today we announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Today we reported fourth quarter and full year 2021 financial results and a corporate update.
Matt Hagood, Analyst, Oppenheimer & Co. Inc. Okay, good morning, everyone. And welcome to the...
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies for cancer, infectious and degenerative diseases, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, and Andrew Pecora, M.D., President of Celularity, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 11:20am ET.
Celularity Inc. a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with...
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a...
Florham Park, N.J. & San Diego, C.A., September 20, 2021: Celularity Inc. (“Celularity”) (Nasdaq: CELU),...
Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25...
Secured funding of approximately $138 million through merger and private placement investment in public equity...
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus...